Among these derivatives, 66 emerged as a promising AD-modifying drug candidate to further develop due to its antioxidant effect by induction of NAD(P)H: quinone oxidoreductase 1 (NQO1 enzyme), which was accompanied by the absence of evident neurotoxic effects up to 20 μM and favorable pharmacokinetic behavior [61]. This evidence concerns the gene NQO1 and Alzheimer disease.